Latest news

• Biohaven gets FDA approval for migraine drug Nurtec ODT

  A successful outcome in those studies would make the drug a potential competitor to three CGRP inhibitors given by subcutaneous injection – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  Teva has however claimed an FDA approval for a three-month regimen for Ajovy. ... Teva meanwhile said Ajovy made $96m last year, while Lilly reported Emgality sales of $163m.

• Teva’s weak pipeline hit by Tourette’s drug trial failure

  It’s one of a clutch of new drugs – that also includes migraine prevention therapy Ajovy (fremanezumab) – that Teva needs to perform well and help it  recover from the double whammy

• Lilly launches migraine med Reyvow at $640 per eight-pill pack

  s second-to-market Ajovy (fremanezumab). ... It also predicts Emgality could hit $1.2bn by 2024, with Ajovy forecast to reach $962m.

• Allergan gets FDA nod for first oral CGRP drug for migraine

  First to market among these the injectables was Amgen/Novartis’ Aimovig (erenumab), and it has since been joined by Eli Lilly’s Emgality (galcanezumab) and Teva’s Ajovy (fremanezumab), with intravenous